tbuckley/cabot-search huggingface dataset:
Research at the National Cancer Institute
Authors: Mider, G. B.
Journal: JNCI Journal of the National Cancer Institute (1957)

Journal Article Research at the National Cancer Institute Get access G. B. Mider G. B. Mider Associate Director in Charge of Research National Cancer Institute, Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 19, Issue 2, August 1957, Pages 191–223, https://doi.org/10.1093/jnci/19.2.191 Published: 01 August 1957
Inflammasome-Dependent Induction of Adaptive NK Cell Memory
Authors: Jasper G. van den Boorn, Christopher Jakobs, Christian Hagen, Marcel Renn, Rosalie M. Luiten, Cornelis J.M. Melief, Thomas Tüting, Natalio Garbi, Gunther Hartmann, Veit Hornung
Journal: Immunity (2016)
High-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support.
Authors: B R Meisenberg
Journal: Journal of Clinical Oncology (1995)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1995.13.7.1826 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 7602373 High-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support. B R MeisenbergxB R MeisenbergSearch for articles by this author https://doi.org/10.1200/JCO.1995.13.7.1826 PDF "High-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support.." Journal of Clinical Oncology, 13(7), pp. 1826–1827© 1995 by American Society of Clinical Oncology
Ga-67 Scintigraphy in Pericarditis Associated with Rheumatoid Arthritis
Authors: ROBERT MANSBERG, JOHN ROBERTS, MARCIN ROMAN
Journal: Clinical Nuclear Medicine (2001)

MANSBERG, ROBERT M.B.B.S., F.R.A.C.P.; ROBERTS, JOHN M.B.B.S., F.R.A.C.P.; ROMAN, MARCIN M.B.B.S. Author Information
Bronchiectasthma and asthmectasis!
Authors: Joan B. Soriano, José Serrano
Journal: European Respiratory Journal (2016)

Respiratory disease can be considered as a species in constant evolution. Due to population growth and ageing only, and apart from the current 1.1 billion smokers, there have never been more respiratory patients ever in history than today [1]. With the latest World Health Organization (WHO) worldwide estimates of 400 million individuals with rhinitis, 334 million asthmatics, 328 million chronic obstructive pulmonary disease (COPD) patients and over 100 million with sleep apnoea, there is plenty of opportunity for the concurrence of two or more respiratory diseases in the same person. Not surprisingly, it is now commonplace in medical journals and conferences to explore for syndromes that combine two respiratory conditions, such as COPD and sleep apnoea, asthma and COPD, lung cancer and pulmonary fibrosis, emphysema and bronchiectasis, etc . A relatively new kid on the block is, perhaps, bronchiectasis and asthma. Both chronic conditions are diagnosed clinically, with or without the help of imaging and lung function, and their flares (or exacerbations) share similar symptoms. Asthma and bronchiectasis: association or overlap <http://ow.ly/YHcJS>
New data on lithium and haloperidol incompatibility
Authors: G Spring, M Frankel
Journal: American Journal of Psychiatry (1981)

The authors describe a case of combined lithium and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of irreversible tardive dyskinesia. This case is similar to four other cases described in the literature and to the neuroleptic malignant syndrome. The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine. Possible mechanisms and preventive measures are discussed.
Methylcholanthrene and the Environment of Paramecium
Authors: George E. Daniel, R. R. Spencer, Dorothy Calnan
Journal: JNCI Journal of the National Cancer Institute (1945)

Methylcholanthrene and the Environment of Paramecium Get access George E. Daniel, George E. Daniel research fellow National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar R. R. Spencer, R. R. Spencer Chief National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar Dorothy Calnan Dorothy Calnan junior bacteriologist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 6, Issue 3, December 1945, Pages 157–160, https://doi.org/10.1093/jnci/6.3.157 Published: 01 December 1945
Bitter Pills
Authors: Adam C. Schaffer, Yonatan Grad, John J. Ross
Journal: New England Journal of Medicine (2010)

A 60-year-old man presented to an urgent care clinic with fatigue, which began a month earlier, and increasing frequency of urination, increasing nighttime urination, and increasing thirst, all of which began during the past week. He had previously been told that he had "prediabetes" and was concerned that his symptoms reflected progression to diabetes mellitus. . . .
Reply
Authors: Monika Ferlitsch, Markus Peck-Radosavljevic, Arnulf Ferlitsch
Journal: Hepatology (2013)

We are thankful to Eapen et al. for their interest in our work and for sharing their data with us. We reported in a large cohort that von Willebrand factor antigen (vWF-Ag)1 might be an easy to use marker to detect portal hypertension, and to predict decompensation and death in cirrhosis patients. As mentioned in our article, it is known that elevated vWF-Ag levels might be a consequence of a reduced clearance of vWF-Ag resulting from decreased expression or activity of ADAMTS13 (vWF-Ag cleaving protease) in patients with cirrhosis.2 A recent publication investigated the potential prognostic value of ADAMTS13 for mortality in liver cirrhosis,3 stating that ADAMTS13 activity may be a useful prognostic marker that is equal or superior to the Child-Pugh score and the Model for Endstage Liver Disease (MELD) score to predict not only the short-term prognosis but also the long-term survival of cirrhosis patients, with similar prognostic levels, compared to the vWF-Ag in our study. These findings suggest a prognostic value both for ADAMTS13 and ULvWF multimers also in our cohort. However, ADAMTS13 assays have very high interassay variability, especially in the middle range,4 although newly developed kits promise improved quality.5 Both analysis of ULvWF multimers and ADAMTS13 are considerably more expensive compared to vWF-Ag analysis. Additionally, they are not available in standard laboratories and they take a long time to perform. This lack of clinical applicability led us to not analyze measurements of ULvWF or ADAMTS13 in our study. MONIKA FERLITSCH, M.D. MARKUS PECK-RADOSAVLJEVIC, M.D. ARNULF FERLITSCH, M.D. Vienna Hepatic Hemodynamic Laboratory, Internal Medicine III, Department of Gastroenterology & Hepatology, Medical University of Vienna, Vienna, Austria
Body Ultrasonography
Authors: Joseph T. Ferrucci
Journal: New England Journal of Medicine (1979)

Organ/Area ApplicationsGallbladderAccuracy rates for sonographic detection of gallstones have steadily increased since the description of B-scan cholecystosonography by Hublitz in 1972.74 Present methods display nonradiopaque stones 3 mm in size, and recently published correlations of sonographic, radiographic and surgical findings have established an 89 to 96 per cent overall detection rate for cholelithiasis75 76 77 78 79 80 81 82 83 equaling the results usually attributed to conventional radiographic oral cholecystography. The present level of diagnostic success derives from concurrent refinements in instrumentation, scanning technics and diagnostic criteria and has advanced ultrasonography to a major role in the evaluation of gallstones.The . . .
Endoscopic ultrasound-guided transmural drainage of a pancreatic collection: case report of a massive hemoperitoneum without intracystic bleeding
Authors: Sébastien Godat, Fabrice Caillol, Erwan Bories, Christian Pesenti, Jean Ratone, Marc Giovannini
Journal: Endoscopy (2015)

A 51-year-old woman was referred for the management of a painful pseudocyst, 50 mm in diameter, in the tail of the pancreas. The pseudocyst had mature walls and was close to the gastrointestinal lumen [1]. The patient had no ascites and no coagulation disorder. Segmental portal hypertension was noted on computed tomographic examination.
Screening for Osteoporosis: U.S. Preventive Services Task Force Recommendation Statement
Journal: Annals of Internal Medicine (2011)

This article has been corrected. The original version (PDF) is appended to this article as a supplement. Description: Update of the 2002 U.S. Preventive Services Task Force (USPSTF) recommendation on screening for osteoporosis. Methods: The USPSTF evaluated evidence on the diagnostic accuracy of risk assessment instruments for osteoporosis and fractures, the performance of dual-energy x-ray absorptiometry and peripheral bone measurement tests in predicting fractures, the harms of screening for osteoporosis, and the benefits and harms of drug therapy for osteoporosis in women and men. Recommendations: The USPSTF recommends screening for osteoporosis in women aged 65 years or older and in younger women whose fracture risk is equal to or greater than that of a 65-year-old white woman who has no additional risk factors. (Grade B recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for osteoporosis in men. (I statement)
Treatment of Phenylketonuria
Authors: H L Levy
Journal: BMJ (1963)

The Medical Research Council of Great Britain has set up a Conference committee to appraise "the practical problems of detection, early treatment, and subsequent care of children suffering from phenylketonuria." The Conference has 20 distin guished members, under the chairmanship of Pro fessor A. A. Moncrieff. Presented here is a condensation of the Report of this Conference, as published in The British Medical Journal of June 29, 1963. Reprints of the entire Report in pamphlet form may be obtained from the Publishing Manager, B. M. A. House, Tavistock Square, London, W.C.1, price Is. 6d., including postage (25 copies or more at Is. each, including postage). In addition to the clinical discussions outlined here, the Report contains a detailed description of the laboratory method for estimation of l-phenyl alanine in blood using l-amino-acid oxidase and an ultrafiltrate of plasma; tables giving the com position of commercially available low-phenyl alanine preparations and the recommended daily vitamin supplements; instructions for construction of a low-phenylalanine diet; and a table listing the phenylalanine content of common foods.
AB0893 Osteoporosis Evaluation and Treatment Depending on Risk Assessment of the Osteoporotic Fractures in Patients with Rheumatoid Arthritis in Russia
Authors: E. Vetkova, I. Dydykina, M. Podvorotova, E. Taskina, A. Smirnov, A. Sinenko, T. Ruskina, D. Peshekhonov, S. Myasoedova, B. Zavodovski, P. Dydykina, E. Petrova, L. Alekseeva, E. Nasonov
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Objectives</h3> Through the Programme of the Russian Association of Rheumatology for the diagnosis, prevention and treatment osteoporosis (OP) in patients with RA we evaluated the ten year probability of major osteoporotic fracture by FRAX for Russia in patients with RA, and identified prevalence osteoporosis treatment in patients with high or low risk of osteoporotic fractures (OF). <h3>Methods</h3> Trough the Programme of a large amount of patients with RA from 12 clinical centers in Russia 560 patients aged 41 to 89 years were selected and have been evaluated the risk of OF by FRAX. <h3>Results</h3> 485 (87%) women and 75 (13%) men were involved in our study. Female average age was 60,46 years, male one was 60,1 years. OP was diagnosed in 97 (17%) patients, 74 (13%) had a history of OF, however, of these people OP treatment was approved only 86 (87%) and 36 (49%), respectively. 185 (33%) patients have indications to approve OP treatment, defined using FRAX, only 57 (31%) of these people treatment was imposed. Assignment of treatment didn9t need for 375 (67%) patients, however treatment was approved 48 (13%) from them. 77 (73%) patients were taking prescribed medications, 49 (60%) of them – bisphosphonates plus calcium and/or vitamin D supplementation, 14 (18%) – calcium and vitamin D, 11 (14%) – calcitonin, 3 (4%) - strontium ranelate. Osteoporosis evaluation (DXA) was performed in 421 (75%) patients, including 54 (72%) patients with history of OF and 128 (69%) patients with indications to approve OP treatment, defined using FRAX. <h3>Conclusions</h3> Osteoporosis management is not quite enough in patients with RA in Russia. There is substantial variation in the quality of risk evaluation of the osteoporotic fractures, osteoporosis evaluation and treatment. Introduction of FRAX for allocation of group of patients with RA with a high risk of fracture will contribute to a personalized approach to approving treatment. <h3>Disclosure of Interest</h3> None declared
SP0065 What Really Works: Engaging Health Care Professionals in Supporting Patients into Work
Authors: D. Cohen
Journal: Annals of the Rheumatic Diseases (2015)

There is a fundamental link between work status, health and well-being (Black, 2008; Waddell et al 2006, 2008). Identifying and addressing work problems early in the management of people with rheumatological conditions is important to improve wellbeing, reduce comorbidity and help prevent work disability, sickness absence and presenteeism (i.e. reduced work ability when at work). Empowering patients to manage their own condition is central to good medical practice. Shared decision-making enables this process, by “clinicians and patients working together to select tests, treatments, management or support packages, based on clinical evidence and the patient9s informed preferences” (Kings Fund 2011). Since 2005 Cardiff University has worked in collaboration with the Royal Colleges, Welsh and UK Government to undertake a programme of work to shift attitudes to the management of work and health in everyday consultations. Work initially focused on General Practitioners. However secondary care specialties that manage long-term conditions in patients of working age (e.g. Rheumatology) must also be targeted. The reasons why Rheumatology teams (doctors, rheumatology nurses and therapists) do not or inadequately address work issues can include; considering work issues as inappropriate to address within health consultations; attaching insufficient importance to work as an issue of concern for patients; and/ or insufficient knowledge, skills and/ or confidence to raise and then address work issues adequately, particularly within the constraints of clinic appointments. Cardiff University have developed and piloted a face-to-face training programme for Rheumatology team members (rheumatologists, nurse specialists, occupational therapists and physiotherapists) to address these issues and raise the importance of discussing work at an early stage in a patient9s journey. To enhance this work Cardiff University has also developed and is piloting a tool to aid “shared decision-making” about work and health for both primary care and secondary care practitioners. My presentation will provide the audience with an over view of the work undertaken and the results of the pilot training programmes <h3>Disclosure of Interest</h3> None declared
NIMG-47PATHOLOGICALLY CONFIRMED VIABLE TUMOR SURROUNDS REGIONS OF PROGRESSIVELY EXPANDING DIFFUSION-RESTRICTED NECROSIS FOLLOWING BEVACIZUMAB TREATMENT
Authors: Peter LaViolette, Nelson Milbach, Jennifer Connelly, Scott Rand, Kathleen Schmainda, Elizabeth Cochran
Journal: Neuro-Oncology (2015)

NIMG-47. PATHOLOGICALLY CONFIRMED VIABLE TUMOR SURROUNDS REGIONS OF PROGRESSIVELY EXPANDING DIFFUSION-RESTRICTED NECROSIS FOLLOWING BEVACIZUMAB TREATMENT Peter LaViolette, Nelson Milbach, Jennifer Connelly, Scott Rand, Kathleen Schmainda, and Elizabeth Cochran; Medical College of Wisconsin, Milwaukee, WI, USA INTRODUCTION: In a subset of recurrent glioblastoma patients, bevacizumab has been shown to induce regions of diffusion restriction. Previous conflicting reportshave found that these lesions contain eitherhypercellular tumor or diffusion restricted necrosis. This study uses whole brain samples to determine both the histological characteristics of the diffusion restricted lesions, and the surrounding tissue. METHODS: Seven patients with bevacizumab induced diffusion restricted lesions were recruited for brain donation for this study. The patient’s brains were sectioned in the same axial orientation as their final clinical imaging session using individualized custom 3d-printed slicing jigs. Clinical imagingacquiredprior to death included diffusion weighted imaging (DWI), T1 pre and post gadolinium contrast, and T2 weighted images. Apparent diffusion coefficient (ADC) maps were calculated from the DWI. Diffusion restriction was defined using radiological criteria. All regions were outside of contrast enhancement, yet within T2 hyperintensity. Specimens were acquired from the brain slice and region that co-localized with the diffusion restriction. Samples were then paraffin embedded, H&E stained, and digitized for interpretation. Each sample was the read by our pathologist to differentiate necrotic regions from viable tumor. RESULTS: In six of seven patients, the diffusion-restricted lesions were progressively growingat the time of the patient’s final scan. In all cases, the diffusion restriction was co-localized to necrotic tissue. In the six progressing patients, the diffusionrestricted necrosis was surrounded by viable hypercellular non-enhancing tumor. The patient without progressively growing diffusion restriction had recurrent tumor elsewhere, not directly adjacent to the diffusion restriction. CONCLUSION: We pathologically confirmed that progressively growing diffusion restriction in patients undergoing bevacizumab treatment indicated necrosis surrounded by viable hypercellular tumor. This information should be considered when choosing to continue or withdraw bevacizumab therapy. Neuro-Oncology 17:v153–v171, 2015. doi:10.1093/neuonc/nov225.47 Published by Oxford University Press on behalf of the Society for Neuro-Oncology 2015.
Re: Jennifer R. Rider, Kathryn M. Wilson, Jennifer A. Sinnott, Rachel S. Kelly, Lorelei A. Muccia, Edward L. Giovannucci. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urol 2016;70:974–82
Authors: Cédric Annweiler, Pierre Bigot, Spyridon N. Karras
Journal: European Urology (2016)
AB0585 The Study on the Uric Acid Level of the Fertile Female Systemic Lupus Erythematosus Patients: Table 1.
Authors: H.-J. Liu, J.-D. Ma, Y.-Q. Mo, D.-H. Zheng, X.-Y. Cai, M.-Y. Xie, L. Dai
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Whether the fertile female systemic lupus erythematosus (SLE) patients have low incidence of hyperuricemia like healthy fertile women? There were few reports yet. <h3>Objectives</h3> To explore the urine acid (UA) level and its influence fators in the fertile female SLE patients. <h3>Methods</h3> Fertile female SLE patients were recruited as well as healthy fertile women as control. Blood UA concentration were tested and compared. In the SLE group, patients were further divided into two subgroups (high UA subgroup and normal UA subgroup, by 358 μmol/l), and the kidney index, SLE disease indicators, SLEDAI score and blood lipid level were compared between them. To determine the independent factors affecting the UA level of SLE patients, binary logistic regression analysis and multiple linear regression analysis were further applied. <h3>Results</h3> 1.The mean age of the SLE group (n=107) and the control group (n=50) were (28.93±7.98) years and (30.34±5.85) years, with no significant difference (t=-1.142, p&lt;0.05). The median disease duration of the SLE group was (25.64±31.11) months. Only seven SLE patients presented renal failure, and the average CRE level of the SLE group was (87.56±63.26) μmol/l.The average SLEDAI was 7.07±5.86. 2.The mean UA concentration of the SLE group and the control group were (367.43±159.86) μmol/l and (296.78±69.87) μmol/l, with remarkable distinction (t=3.852, P&lt;0.001). The incidence of high UA in the SLE group and the control group were 42.06% and 14%, with significant difference (χ<sup>2</sup> =12.109, P&lt;0.05). 3.16 SLE patients received the medications that may increase the UA level, including azathioprine and cyclosporin. The binary logistic regression analysis indicated that these medications were not the risk factor of high UA in SLE patients (95%CI 0.268–2.389, P&gt;0.05). 4.In the high UA subgroup (n=45) of the SLE group, CRE, TG, LDL and HDL were dramatically higher than those of the normal UA subgroup (n=62, t=2.582, 2.941, -2.691, all P&lt;0.05), and C3 was markedly lower than that of the normal UA subgroup (t=-3.225, P&lt;0.05). The positive rates of anti-dsDNA and urine blood of the high UA subgroup were significantly higher than those of the normal UA subgroup (χ<sup>2</sup> =7.010, 7.489, both P&lt;0.05). 5.The multiple linear regression analysis indicated that CRE, TG, HDL and urine blood were the independent factors for UA level of SLE patients (t=4.383, 3.182, -2.036, 2.692, all P&lt;0.05, table 1). <h3>Conclusions</h3> The fertile female SLE patients showed higher incidence of hyperuricemia than healthy fertile women, and CRE, TG, HDL and urine blood were the independent factors for UA level. <h3>Disclosure of Interest</h3> None declared
Electron Microscopy of the H-1 Virus. I. Morphology of the Virus and a Possible Virus-Host Relationship&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Satish Chandra, Helene Wallace Toolan
Journal: JNCI Journal of the National Cancer Institute (1961)

An electron microscopic study of the H-1 virus, derived originally from a transplantable human tumor, shows that the virus consists of a dense core approximately 150 A in diameter. A coat 75 A wide, not made visible by the techniques used, may encircle the core, which makes the diameter of the “complete” virus 300 A. Virus particles have been observed enclosed in gray bodies in the cytoplasm of the Küpffer cells, in the interstitial cells of the kidney from 3- to 11-day-old infected hamsters, and in the chondrocytes of embryonic hamster cells incubated in media inoculated with the virus. Changes in the mitochondrial structure suggest that these organelles are intimately involved in a virus-cell interaction.